Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report)’s stock price was up 10.2% during trading on Thursday . The stock traded as high as $22.82 and last traded at $22.7940. Approximately 4,992 shares traded hands during trading, a decline of 98% from the average session volume of 316,654 shares. The stock had previously closed at $20.69.
Analysts Set New Price Targets
Several equities analysts have issued reports on the stock. BTIG Research restated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Finally, The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and an average price target of $27.40.
Kestra Medical Technologies Trading Down 1.2%
Insider Transactions at Kestra Medical Technologies
In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares in the company, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 45,000 shares of company stock worth $927,150. Insiders own 3.60% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of KMTS. Price T Rowe Associates Inc. MD lifted its holdings in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares during the period. Brown Advisory Inc. increased its holdings in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the period. Eventide Asset Management LLC lifted its stake in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after purchasing an additional 65,288 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares in the last quarter.
About Kestra Medical Technologies
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Articles
- Five stocks we like better than Kestra Medical Technologies
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
- Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story
- Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
